Handok develops ‘Drug combination for diabetes and its
comorbidities’, which is selected as a joint international research support
project for innovative pharmaceutical companies

-A good
chance for entering the global market… Maximum research fund of 830 million won
will be offered over the course of 1 year and 9 months

‘Drug combination for diabetes and its
comorbidities’, being developed by Handok has been selected as a ‘joint
international research support project for innovative pharmaceutical companies’
by Ministry of Health and Welfare.

‘Joint international research support project for innovative
pharmaceutical companies’, conducted by Korea Health Industry Development
Institute under Ministry of Health and Welfare, supports cooperative research
of innovative pharmaceutical companies so they may maintain technological
competitiveness to develop blockbuster novel drugs and expand their businesses
abroad. ‘Joint international research support project for innovative
pharmaceutical companies’ seeks for support of development of global-level novel
drugs, which requires a joint international research with an overseas
institution.

Handok’s ‘drug combination for diabetes and its
comorbidities’ will treat two diseases at once, which will hopefully improve
patient adherence and enhance convenience as well as maximize the treatment effect.
Handok had the possibility recognized for the ‘drug combination for diabetes
and its comorbidities’ to enter the global market through its selection as ‘joint
international research support project for innovative pharmaceutical companies’,
as well as receiving maximum research fund of 830 million over the course of 1
year and 9 months. Handok will also apply advanced QbD (Quality by Design) in
the development of ‘drug combination for diabetes and its
comorbidities’, keeping in with the recent global trend. Therefore, ‘PAT (Process
Analytical Technology) and RTRT (Real Time Release Testing) model development’
will be conducted jointly with distinguished researchers from abroad.

Wooik Jang, vice-president of the headquarter of research
and development for Handok mentioned that “The selection of the project had accelerated
the development of ‘drug combination for diabetes and its comorbidities’.
Through a joint international research, we will successfully develop a
world-class novel drug which will be exported overseas in the future.”